Rebecca Leyland

List of Publications by Year
in descending order

17 papers	1,186 citations	840776 11 h-index	1199594 12 g-index
17 all docs	17 docs citations	17 times ranked	2547 citing authors

#	Article	IF	Citations
1	Recombinant Newcastle Disease Virus Immunotherapy Drives Oncolytic Effects and Durable Systemic Antitumor Immunity. Molecular Cancer Therapeutics, 2021, 20, 1723-1734.	4.1	5
2	The Extrinsic and Intrinsic Roles of PD-L1 and Its Receptor PD-1: Implications for Immunotherapy Treatment. Frontiers in Immunology, 2020, 11, 568931.	4.8	100
3	MicroRNA-155 is essential for the optimal proliferation and survival of plasmablast B cells. Life Science Alliance, 2019, 2, e201800244.	2.8	17
4	Epigenomic Modifications Mediating Antibody Maturation. Frontiers in Immunology, 2018, 9, 355.	4.8	28
5	A Novel Murine GITR Ligand Fusion Protein Induces Antitumor Activity as a Monotherapy That Is Further Enhanced in Combination with an OX40 Agonist. Clinical Cancer Research, 2017, 23, 3416-3427.	7.0	42
6	Rational Selection of Syngeneic Preclinical Tumor Models for Immunotherapeutic Drug Discovery. Cancer Immunology Research, 2017, 5, 29-41.	3.4	321
7	Abstract 4604: MEDI1873, a GITR ligand fusion protein (GITRL FP), induces effector T-cell proliferation, modulates T-regulatory cell function and has the potential to combine with checkpoint inhibitors. , 2017, , .		0
8	Abstract 561: MEDI1873: A novel hexameric GITRL fusion protein with potent agonsitic and immunomodulatory activities in preclinical systems. , 2016, , .		1
9	Phenotypic screening reveals TNFR2 as a promising target for cancer immunotherapy. Oncotarget, 2016, 7, 68278-68291.	1.8	48
10	Abstract 4902: A mouse GITRL fusion protein drives T-cell activation and antitumor activity in preclinical mouse models of cancer. , 2016, , .		0
11	Abstract 4186: Syngenomic fingerprint: the biomic characterization of the mouse syngeneic tumor models. , 2016, , .		0
12	A mouse GITRl fusion protein drives T cell activation and antitumor activity in preclinical mouse models of cancer. , 2015, 3, .		0
13	MicroRNA-155 controls affinity-based selection by protecting c-MYC+ B cells from apoptosis. Journal of Clinical Investigation, 2015, 126, 377-388.	8.2	41
14	The miR-155â€“PU.1 axis acts on Pax5 to enable efficient terminal B cell differentiation. Journal of Experimental Medicine, 2014, 211, 2183-2198.	8.5	83
15	miRâ€155: an ancient regulator of the immune system. Immunological Reviews, 2013, 253, 146-157.	6.0	286
16	MicroRNA-155 Is Required for Mycobacterium bovis BCG-Mediated Apoptosis of Macrophages. Molecular and Cellular Biology, 2012, 32, 2239-2253.	2.3	126
17	Characterisation of 5â€HT_{3C}, 5â€HT_{3D} and 5â€HT_{3E} receptor subunits: evolution, distribution and function. Journal of Neurochemistry, 2009, 108, 384-396.	3.9	88